|
PL3243526T3
(pl)
|
2010-07-06 |
2020-05-18 |
Glaxosmithkline Biologicals S.A. |
Dostarczanie rna w celu wyzwolenia wielu szlaków immunologicznych
|
|
PL2591114T3
(pl)
|
2010-07-06 |
2017-08-31 |
Glaxosmithkline Biologicals Sa |
Immunizacja dużych ssaków małymi dawkami rna
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
MX341989B
(es)
|
2010-08-31 |
2016-09-09 |
Novartis Ag * |
Liposomas pequeños para el suministro de arn que codifica el inmunogeno.
|
|
HUE061068T2
(hu)
|
2010-08-31 |
2023-05-28 |
Glaxosmithkline Biologicals Sa |
Pegilált liposzómák immunogént kódoló RNS szállítására
|
|
EP4098324A1
(en)
|
2010-10-11 |
2022-12-07 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
ES2987057T3
(es)
|
2011-06-08 |
2024-11-13 |
Translate Bio Inc |
Lípidos escindibles
|
|
JP6184945B2
(ja)
|
2011-06-08 |
2017-08-23 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
|
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
PT3981437T
(pt)
|
2014-04-23 |
2025-01-15 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
|
CA2984125A1
(en)
|
2015-04-27 |
2016-11-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
KR20180033586A
(ko)
|
2015-08-04 |
2018-04-03 |
듀크 유니버시티 |
전달을 위한 유전적으로 인코딩된 내재적으로 무질서화된 스텔스 중합체 및 이의 이용 방법
|
|
SMT202200178T1
(it)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti terapeutici
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
EP3718565B1
(en)
|
2015-10-22 |
2022-04-27 |
ModernaTX, Inc. |
Respiratory virus vaccines
|
|
JP6921833B2
(ja)
|
2015-10-22 |
2021-08-18 |
モデルナティーエックス， インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018081480A1
(en)
|
2016-10-26 |
2018-05-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
PL3386484T3
(pl)
*
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
EP3390630B1
(en)
|
2015-12-17 |
2025-01-22 |
ModernaTX, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
PL3394030T3
(pl)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
|
|
EP3458107B1
(en)
|
2016-05-18 |
2024-03-13 |
ModernaTX, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
US20200085916A1
(en)
*
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
MY201498A
(en)
|
2016-05-18 |
2024-02-27 |
Modernatx Inc |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
US20190382774A1
(en)
*
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
IL263079B2
(en)
|
2016-05-18 |
2024-05-01 |
Modernatx Inc |
Polynucleotides encoding relaxin
|
|
US12123030B2
(en)
|
2016-05-18 |
2024-10-22 |
Modernatx, Inc. |
Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
EP3515928A4
(en)
|
2016-09-23 |
2020-04-01 |
Duke University |
Unstructured non-repetitive polypeptides having lcst behavior
|
|
EP4667565A2
(en)
|
2016-10-20 |
2025-12-24 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
KR20190086681A
(ko)
|
2016-10-26 |
2019-07-23 |
모더나티엑스, 인크. |
면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법
|
|
AU2017350488B2
(en)
|
2016-10-26 |
2022-06-23 |
Acuitas Therapeutics Inc. |
Lipid nanoparticle mRNA vaccines
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
WO2018081638A1
(en)
|
2016-10-27 |
2018-05-03 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
US11851389B2
(en)
|
2016-11-08 |
2023-12-26 |
Ramot At Tel-Aviv University Ltd. |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538146A4
(en)
|
2016-11-11 |
2020-07-15 |
ModernaTX, Inc. |
INFLUENZA VACCINE
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
JP7317715B2
(ja)
|
2017-01-11 |
2023-07-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変ｒｎａ
|
|
WO2018132732A1
(en)
|
2017-01-12 |
2018-07-19 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
EA201991804A1
(ru)
|
2017-02-01 |
2020-02-07 |
МОДЕРНАТиЭкс, ИНК. |
ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
AU2018234814B2
(en)
|
2017-03-15 |
2022-06-30 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
LT3596041T
(lt)
|
2017-03-15 |
2023-01-25 |
Modernatx, Inc. |
Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
JP7162021B2
(ja)
|
2017-03-17 |
2022-10-27 |
ニューカッスル ユニバーシティ |
筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達
|
|
EP3601576A1
(en)
|
2017-03-24 |
2020-02-05 |
CureVac AG |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018200892A1
(en)
|
2017-04-27 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
|
|
CN116693411A
(zh)
|
2017-04-28 |
2023-09-05 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
EP3624824B1
(en)
|
2017-05-16 |
2024-07-10 |
Translate Bio, Inc. |
Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
|
|
WO2018225871A1
(ja)
*
|
2017-06-09 |
2018-12-13 |
協和発酵キリン株式会社 |
カチオン性脂質としての化合物
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US10780183B2
(en)
|
2017-06-19 |
2020-09-22 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of Friedreich's ataxia
|
|
US11680083B2
(en)
|
2017-06-30 |
2023-06-20 |
Duke University |
Order and disorder as a design principle for stimuli-responsive biopolymer networks
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US12065396B2
(en)
|
2017-08-17 |
2024-08-20 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
WO2019126593A1
(en)
|
2017-12-20 |
2019-06-27 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
|
BR112020013201A2
(pt)
|
2017-12-27 |
2020-12-01 |
Takeda Pharmaceutical Company Limited |
nanopartícula lipídica, medicamento, métodos para expressar um receptor, para prevenir ou tratar câncer e para produzir um medicamento, uso da nanopartícula lipídica e do imunócito ex vivo, composição, imunócito ex vivo, e, célula ex vivo
|
|
US12296018B2
(en)
|
2018-01-26 |
2025-05-13 |
Duke University |
Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
JP2021512090A
(ja)
|
2018-01-30 |
2021-05-13 |
モデルナティーエックス， インコーポレイテッド |
免疫細胞に薬剤を送達するための組成物及び方法
|
|
EP3773702A2
(en)
|
2018-04-05 |
2021-02-17 |
CureVac AG |
Novel yellow fever nucleic acid molecules for vaccination
|
|
JP7613685B2
(ja)
|
2018-04-17 |
2025-01-15 |
キュアバック エスイー |
新規ｒｓｖ ｒｎａ分子及びワクチン接種用組成物
|
|
US12257308B2
(en)
|
2018-04-30 |
2025-03-25 |
Duke University |
Stimuli-responsive PEG-like polymer-based drug delivery platform
|
|
WO2019222277A1
(en)
|
2018-05-15 |
2019-11-21 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7488193B2
(ja)
*
|
2018-05-24 |
2024-05-21 |
トランスレイト バイオ， インコーポレイテッド |
チオエステルカチオン性脂質
|
|
WO2019232103A1
(en)
|
2018-05-30 |
2019-12-05 |
Translate Bio, Inc. |
Messenger rna vaccines and uses thereof
|
|
CN112533909B
(zh)
|
2018-05-30 |
2024-11-15 |
川斯勒佰尔公司 |
维生素阳离子脂质
|
|
US11547666B2
(en)
|
2018-05-30 |
2023-01-10 |
Translate Bio, Inc. |
Cationic lipids comprising a steroidal moiety
|
|
JP2021525743A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ， インコーポレイテッド |
リン酸エステルカチオン性脂質
|
|
JP7646362B2
(ja)
|
2018-06-18 |
2025-03-17 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋肉特異的マイクロジストロフィンのアデノ随伴ウイルスベクターデリバリー
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
CN112638362B
(zh)
|
2018-07-23 |
2025-06-13 |
川斯勒佰尔公司 |
信使rna的干粉制剂
|
|
WO2020028806A1
(en)
|
2018-08-02 |
2020-02-06 |
Duke University |
Dual agonist fusion proteins
|
|
US11357726B2
(en)
|
2018-08-29 |
2022-06-14 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
WO2020056304A1
(en)
|
2018-09-14 |
2020-03-19 |
Modernatx, Inc. |
Methods and compositions for treating cancer using mrna therapeutics
|
|
WO2020056294A1
(en)
|
2018-09-14 |
2020-03-19 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
CA3113436A1
(en)
*
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2019345067A1
(en)
*
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12329857B2
(en)
|
2018-09-21 |
2025-06-17 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
EP3860656A1
(en)
|
2018-10-01 |
2021-08-11 |
Johannes-Gutenberg-Universität Mainz |
Rna particles comprising polysarcosine
|
|
IL317488A
(en)
*
|
2018-10-02 |
2025-02-01 |
Intellia Therapeutics Inc |
Ionizable lipid amines
|
|
AU2019361129A1
(en)
*
|
2018-10-18 |
2021-05-20 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
BR112021007360A2
(pt)
|
2018-10-18 |
2021-07-20 |
Takeda Pharmaceutical Company Limited |
métodos para ativar/proliferar células t, para distribuir um ácido nucleico em células t e para produzir um medicamento, célula t, medicamento, cultura de células, composição, e, kit para distribuir um ácido nucleico em células t
|
|
KR20210090634A
(ko)
|
2018-10-19 |
2021-07-20 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 무펌프 캡슐화
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
AU2019377525B2
(en)
|
2018-11-09 |
2025-10-16 |
Translate Bio, Inc. |
Multi-PEG lipid compounds
|
|
BR112021008974A2
(pt)
|
2018-11-09 |
2021-08-03 |
Translate Bio, Inc. |
lipídios de 2,5-dioxopiperazina com frações éster, tioéster, dissulfeto e anidrido intercaladas
|
|
WO2020097379A2
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
US20220096612A1
(en)
|
2018-11-12 |
2022-03-31 |
Translatebioinc |
Methods for inducing immune tolerance
|
|
EP3883917B1
(en)
|
2018-11-21 |
2024-01-24 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
CA3125588A1
(en)
|
2019-01-07 |
2020-07-16 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
AU2020205717B2
(en)
|
2019-01-11 |
2025-09-11 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
WO2020214946A1
(en)
|
2019-04-18 |
2020-10-22 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
EP3959195B1
(en)
|
2019-04-22 |
2023-11-08 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
US12453759B2
(en)
|
2019-05-03 |
2025-10-28 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
AU2020268388A1
(en)
|
2019-05-07 |
2021-12-02 |
Modernatx, Inc. |
Polynucleotides for disrupting immune cell activity and methods of use thereof
|
|
US20230086537A1
(en)
|
2019-05-07 |
2023-03-23 |
Modernatx, Inc. |
Differentially expressed immune cell micrornas for regulation of protein expression
|
|
JP7686574B2
(ja)
|
2019-05-22 |
2025-06-02 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状ｒｎａ組成物及び方法
|
|
WO2020243540A1
(en)
|
2019-05-31 |
2020-12-03 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
JP7744011B2
(ja)
|
2019-06-07 |
2025-09-25 |
スクライブ・セラピューティクス・インコーポレイテッド |
操作されたｃａｓｘシステム
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
AU2020295796A1
(en)
|
2019-06-18 |
2022-02-10 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and HBV-targeting rnai
|
|
EP3986454A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
KR20220041079A
(ko)
|
2019-06-18 |
2022-03-31 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합
|
|
US20250041386A1
(en)
|
2019-06-18 |
2025-02-06 |
Janssen Sciences Ireland Unlimited Company |
Recombinant Interleukin 12 Construct and Uses Thereof
|
|
EP3986563A1
(en)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
JP7724161B2
(ja)
|
2019-06-21 |
2025-08-15 |
トランスレイト バイオ， インコーポレイテッド |
トリシンおよびクエン酸脂質
|
|
KR20220078557A
(ko)
|
2019-07-08 |
2022-06-10 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
JP7759311B2
(ja)
|
2019-07-19 |
2025-10-23 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
リコンビナーゼ組成物及び使用方法
|
|
JP7769325B2
(ja)
|
2019-07-23 |
2025-11-13 |
株式会社東芝 |
Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
|
|
JP7764363B2
(ja)
|
2019-07-23 |
2025-11-05 |
トランスレイト バイオ， インコーポレイテッド |
ｍＲＮＡ担持脂質ナノ粒子の安定性組成物および作製のプロセス
|
|
US20220280639A1
(en)
|
2019-07-31 |
2022-09-08 |
Modernatx, Inc. |
Compositions and methods for delivery of rna interference agents to immune cells
|
|
JP7766583B2
(ja)
|
2019-08-07 |
2025-11-10 |
モデルナティエックス インコーポレイテッド |
強化された薬剤送達のための組成物及び方法
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
EP4013880A1
(en)
|
2019-08-14 |
2022-06-22 |
CureVac AG |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
JP7700101B2
(ja)
|
2019-09-06 |
2025-06-30 |
ジェネレーション バイオ カンパニー |
閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
CN114728886B
(zh)
*
|
2019-09-19 |
2024-04-12 |
摩登纳特斯有限公司 |
用于细胞内递送治疗剂的含碳酸酯的脂质化合物和组合物
|
|
AU2020348376A1
(en)
|
2019-09-20 |
2022-04-07 |
Translate Bio, Inc. |
mRNA encoding engineered CFTR
|
|
WO2021061707A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
|
EP4045527A1
(en)
|
2019-10-15 |
2022-08-24 |
ModernaTX, Inc. |
Mrnas encoding immune modulating polypeptides and uses thereof
|
|
JP2022553042A
(ja)
|
2019-10-21 |
2022-12-21 |
トランスレイト バイオ， インコーポレイテッド |
メッセンジャーｒｎａの組成物、方法および使用
|
|
MX2022006033A
(es)
|
2019-11-22 |
2022-06-22 |
Generation Bio Co |
Lipidos ionizables y composiciones de nanoparticulas de estos.
|
|
EP3920976B1
(en)
|
2019-12-04 |
2023-07-19 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
EP4076400A1
(en)
|
2019-12-20 |
2022-10-26 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
KR20220142432A
(ko)
|
2019-12-20 |
2022-10-21 |
트랜슬레이트 바이오 인코포레이티드 |
메신저 rna의 직장 전달
|
|
WO2021141969A1
(en)
*
|
2020-01-09 |
2021-07-15 |
Guide Therapeutics, Inc. |
Nanomaterials
|
|
AU2021205337A1
(en)
|
2020-01-10 |
2022-07-21 |
Modernatx, Inc. |
Methods of making tolerogenic dendritic cells
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
US20230130155A1
(en)
|
2020-01-30 |
2023-04-27 |
Modernatx, Inc. |
Mrnas encoding metabolic reprogramming polypeptides and uses thereof
|
|
DE202021003575U1
(de)
|
2020-02-04 |
2022-01-17 |
Curevac Ag |
Coronavirus-Vakzine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
CA3173035A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
|
AU2021232924C1
(en)
*
|
2020-03-11 |
2025-07-24 |
Advansix Resins & Chemicals Llc |
Surfactants for healthcare products
|
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
KR102701635B1
(ko)
|
2020-03-11 |
2024-08-30 |
어드밴식스 레진즈 앤드 케미컬즈 엘엘씨 |
오일 및 가스 생산을 위한 계면활성제
|
|
EP4121453A2
(en)
|
2020-03-20 |
2023-01-25 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
JP2023520763A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
|
|
CN115667530A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒dna载体和其用于表达因子ix治疗剂的用途
|
|
BR112022019369A2
(pt)
|
2020-03-27 |
2022-12-13 |
Generation Bio Co |
Lipídios e composições de nanopartículas dos mesmos
|
|
KR20220161316A
(ko)
|
2020-03-30 |
2022-12-06 |
비온테크 에스이 |
Claudin-18.2를 표적화하는 rna 조성물
|
|
GB2632564B
(en)
|
2020-04-09 |
2025-06-18 |
Verve Therapeutics Inc |
Base editing of angptl3 and methods of using same for treatment of disease
|
|
AU2021252164A1
(en)
|
2020-04-09 |
2022-12-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
US12023376B1
(en)
|
2020-04-17 |
2024-07-02 |
Triad National Security, Llc |
Conserved region T cell vaccines for coronavirus and methods of use
|
|
CA3174215A1
(en)
|
2020-04-22 |
2021-10-28 |
Ugur Sahin |
Coronavirus vaccine
|
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
WO2021226436A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
|
WO2021226468A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
WO2021231697A1
(en)
|
2020-05-14 |
2021-11-18 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CA3183399A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
US20240042015A1
(en)
|
2020-05-19 |
2024-02-08 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
TW202208629A
(zh)
|
2020-05-20 |
2022-03-01 |
美商旗艦先鋒創新有限責任公司 |
免疫原性組成物及其用途
|
|
MX2022014653A
(es)
|
2020-05-20 |
2023-02-16 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de antigeno de coronavirus y sus usos.
|
|
WO2021239880A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
EP4158031A1
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
AU2021281453A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
WO2021257595A1
(en)
|
2020-06-15 |
2021-12-23 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
EP4178613A1
(en)
|
2020-07-08 |
2023-05-17 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
JP2023535632A
(ja)
|
2020-07-27 |
2023-08-18 |
アンジャリウム バイオサイエンシズ エージー |
Ｄｎａ分子の組成物、その作製方法、及びその使用方法
|
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
JP2023538260A
(ja)
|
2020-08-06 |
2023-09-07 |
モダーナティエックス・インコーポレイテッド |
ペイロード分子を気道上皮に送達するための組成物
|
|
CN114073677B
(zh)
*
|
2020-08-20 |
2023-06-09 |
深圳深信生物科技有限公司 |
一种脂质纳米颗粒
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
CN116157148A
(zh)
|
2020-09-03 |
2023-05-23 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
CA3194863A1
(en)
|
2020-10-06 |
2022-04-14 |
Shrirang KARVE |
Improved process and formulation of lipid nanoparticles
|
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
|
AU2021361986A1
(en)
|
2020-10-12 |
2023-06-15 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
WO2022081750A1
(en)
*
|
2020-10-14 |
2022-04-21 |
George Mason Research Foundation, Inc. |
Ionizable lipids and methods of manufacture and use thereof
|
|
JP2023548587A
(ja)
|
2020-11-09 |
2023-11-17 |
トランスレイト バイオ， インコーポレイテッド |
コドン最適化したｍＲＮＡの送達のための改善された組成物
|
|
AU2021377746A1
(en)
*
|
2020-11-16 |
2023-06-08 |
BioNTech SE |
Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
|
|
CN116669709A
(zh)
*
|
2020-11-16 |
2023-08-29 |
生物技术公司 |
包含颗粒和mRNA的药物组合物及其制备和储存的方法
|
|
US20240041785A1
(en)
|
2020-11-16 |
2024-02-08 |
BioNTech SE |
Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
|
|
EP4243788A1
(en)
*
|
2020-11-16 |
2023-09-20 |
BioNTech SE |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
|
WO2022218503A1
(en)
*
|
2021-04-12 |
2022-10-20 |
BioNTech SE |
Lnp compositions comprising rna and methods for preparing, storing and using the same
|
|
WO2022101461A1
(en)
*
|
2020-11-16 |
2022-05-19 |
BioNTech SE |
Enhanced formulation stabilization and improved lyophilization processes
|
|
US11421015B2
(en)
|
2020-12-07 |
2022-08-23 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
US11058751B1
(en)
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
CN116710115A
(zh)
|
2020-11-20 |
2023-09-05 |
思维疗法股份有限公司 |
用于优化的肽疫苗的组合物和方法
|
|
IL303165A
(en)
|
2020-11-25 |
2023-07-01 |
Translate Bio Inc |
Stable liquid lipid nanoparticle formulations
|
|
WO2022112855A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
|
CN113185421B
(zh)
*
|
2020-11-27 |
2022-01-25 |
广州市锐博生物科技有限公司 |
脂质化合物及其组合物
|
|
EP4025556A4
(en)
*
|
2020-11-27 |
2023-08-09 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
|
EP4256054A1
(en)
|
2020-12-03 |
2023-10-11 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
AU2021405281A1
(en)
|
2020-12-22 |
2023-07-06 |
Glaxosmithkline Biologicals Sa |
Rna vaccine against sars-cov-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022140702A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering, Inc. |
Compositions of modified trems and uses thereof
|
|
WO2022146654A1
(en)
|
2020-12-28 |
2022-07-07 |
Janssen Pharmaceuticals, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
WO2022155404A1
(en)
|
2021-01-14 |
2022-07-21 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
WO2022152109A2
(en)
*
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4204389A2
(en)
*
|
2021-01-14 |
2023-07-05 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4277601A1
(en)
*
|
2021-01-15 |
2023-11-22 |
Pfizer Inc. |
Methods for producing of lipids
|
|
IL303845A
(en)
|
2021-01-20 |
2023-08-01 |
Beam Therapeutics Inc |
Nanomaterials include a degradable property
|
|
WO2022162027A2
(en)
|
2021-01-27 |
2022-08-04 |
Curevac Ag |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US20240124396A1
(en)
*
|
2021-02-07 |
2024-04-18 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Amino lipid compound, preparation method therefor, and use thereof
|
|
CN112961091B
(zh)
*
|
2021-02-07 |
2022-06-17 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物及其制备方法和用途
|
|
CN117157101A
(zh)
|
2021-02-08 |
2023-12-01 |
德克萨斯大学系统董事会 |
不饱和的树枝状聚合物组合物、有关的制剂、及其使用方法
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
AU2022246065A1
(en)
|
2021-03-22 |
2023-10-12 |
Recode Therapeutics, Inc. |
Compositions and methods for targeted delivery to cells
|
|
MX2023011243A
(es)
|
2021-03-23 |
2023-12-14 |
Recode Therapeutics Inc |
Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
|
|
EP4313115A1
(en)
|
2021-03-25 |
2024-02-07 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
|
JP2024511154A
(ja)
|
2021-03-25 |
2024-03-12 |
ショット ファーマ アクチェンゲゼルシャフト ウント コンパニー コマンディートゲゼルシャフト アウフ アクチェン |
医薬品用の容器
|
|
US20240181037A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
|
US20240229109A1
(en)
|
2021-04-01 |
2024-07-11 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
CN115197078B
(zh)
*
|
2021-04-08 |
2024-06-04 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
WO2022215036A1
(en)
|
2021-04-08 |
2022-10-13 |
Vaxthera Sas |
Coronavirus vaccine comprising a mosaic protein
|
|
WO2022214026A1
(zh)
*
|
2021-04-08 |
2022-10-13 |
厦门赛诺邦格生物科技股份有限公司 |
一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用
|
|
US20240208894A1
(en)
*
|
2021-04-09 |
2024-06-27 |
Pfizer Inc. |
Methods for producing of lipids
|
|
AU2022256732A1
(en)
|
2021-04-12 |
2023-10-19 |
Biontech Delivery Technologies Gmbh |
Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
|
|
CA3215389C
(en)
*
|
2021-04-13 |
2024-06-18 |
Xiangrong SONG |
Ionizable lipids and compositions for nucleic acid delivery
|
|
CA3215606A1
(en)
|
2021-04-19 |
2022-10-27 |
Shrirang KARVE |
Improved compositions for delivery of mrna
|
|
AU2022260111A1
(en)
|
2021-04-20 |
2023-11-30 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
|
EP4329885A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
US11464842B1
(en)
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4334944A1
(en)
|
2021-05-04 |
2024-03-13 |
BioNTech SE |
Immunogen selection
|
|
AU2022281746B2
(en)
|
2021-05-24 |
2025-01-16 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CA3220689A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Ciaran LAWLOR |
Lipid nanoparticles and methods of use thereof
|
|
TW202317767A
(zh)
|
2021-06-10 |
2023-05-01 |
美商歐納醫療公司 |
環狀rna組合物及方法
|
|
IL309145A
(en)
|
2021-06-14 |
2024-02-01 |
Generation Bio Co |
Cationic lipids and their compositions
|
|
EP4183770A1
(en)
|
2021-11-22 |
2023-05-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Continuous flow process for production of cationic lipids
|
|
CA3224056A1
(en)
|
2021-06-24 |
2022-12-29 |
Peter Seeberger |
Continuous flow process for production of cationic lipids
|
|
WO2023278754A1
(en)
|
2021-07-01 |
2023-01-05 |
Translate Bio, Inc. |
Compositions for delivery of mrna
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
TW202327647A
(zh)
|
2021-07-15 |
2023-07-16 |
德商拜恩迪克公司 |
用以治療cldn6陽性癌症之藥劑
|
|
CN113264842B
(zh)
*
|
2021-07-21 |
2022-03-01 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
US20240336945A1
(en)
|
2021-07-26 |
2024-10-10 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
IL309952A
(en)
|
2021-07-29 |
2024-03-01 |
BioNTech SE |
Compositions and methods for treating melanoma
|
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
|
JP2024528983A
(ja)
|
2021-08-04 |
2024-08-01 |
モデルナティエックス インコーポレイテッド |
キメラ代謝リプログラミングポリペプチドをコードするｍＲＮＡ及びその使用
|
|
WO2023015200A1
(en)
*
|
2021-08-04 |
2023-02-09 |
The Trustees Of The University Of Pennsylvania |
Amniotic fluid stabilized compositions and methods for in utero delivery of therapeutic agents
|
|
CN115703713B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115703714B
(zh)
*
|
2021-08-13 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
CN115710192B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710193B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115710191B
(zh)
*
|
2021-08-23 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
EP4141013A1
(en)
|
2021-08-31 |
2023-03-01 |
Studiengesellschaft Kohle mbH |
Stereochemically pure lipids for nucleic acid delivery
|
|
WO2023030635A1
(en)
|
2021-09-02 |
2023-03-09 |
BioNTech SE |
Potency assay for therapeutic potential of coding nucleic acid
|
|
CN115745819B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
AU2022336209B2
(en)
|
2021-09-03 |
2025-10-16 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
MX2024002725A
(es)
|
2021-09-03 |
2024-03-15 |
CureVac SE |
Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina.
|
|
CA3232386A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
TW202325263A
(zh)
|
2021-09-14 |
2023-07-01 |
美商雷納嘉德醫療管理公司 |
非環狀脂質及其使用方法
|
|
AR127073A1
(es)
|
2021-09-17 |
2023-12-13 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
EP4408825A1
(en)
|
2021-09-30 |
2024-08-07 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
IL311855A
(en)
|
2021-10-08 |
2024-05-01 |
Pfizer |
Immunogenic lnp compositions and methods thereof
|
|
AR127312A1
(es)
*
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
|
TW202327646A
(zh)
|
2021-10-15 |
2023-07-16 |
美商輝瑞大藥廠 |
Rna分子
|
|
EP4419706A1
(en)
|
2021-10-18 |
2024-08-28 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
AU2022374004A1
(en)
|
2021-10-22 |
2024-05-02 |
BioNTech SE |
Compositions for administration of different doses of rna
|
|
WO2023069498A1
(en)
|
2021-10-22 |
2023-04-27 |
Senda Biosciences, Inc. |
Mrna vaccine composition
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
JP2024540170A
(ja)
|
2021-11-01 |
2024-10-31 |
モデルナティエックス インコーポレイテッド |
インテグリンベータ－６をコードするポリヌクレオチド及びその使用方法
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
CN118541346A
(zh)
|
2021-11-08 |
2024-08-23 |
奥纳治疗公司 |
用于递送环状多核苷酸的脂质纳米颗粒组合物
|
|
WO2023083434A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
|
AU2022388747A1
(en)
|
2021-11-10 |
2024-06-20 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
EP4429644A1
(en)
|
2021-11-12 |
2024-09-18 |
ModernaTX, Inc. |
Compositions for the delivery of payload molecules to airway epithelium
|
|
AU2022394985A1
(en)
|
2021-11-16 |
2024-05-30 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4436549A1
(en)
|
2021-11-22 |
2024-10-02 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
CA3238764A1
(en)
|
2021-11-23 |
2023-06-01 |
Siddharth Patel |
A bacteria-derived lipid composition and use thereof
|
|
AU2022397292A1
(en)
|
2021-11-24 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
|
AU2022397300A1
(en)
|
2021-11-24 |
2024-06-27 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
AR127892A1
(es)
*
|
2021-12-10 |
2024-03-06 |
Modernatx Inc |
Compuestos y composiciones para la administración de agentes terapéuticos
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
MX2024007307A
(es)
|
2021-12-17 |
2024-08-06 |
Flagship Pioneering Innovations Vi Llc |
Métodos de enriquecimiento de arn circular en condiciones desnaturalizantes.
|
|
WO2023111907A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
US20250051386A1
(en)
|
2021-12-22 |
2025-02-13 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
US20230201817A1
(en)
|
2021-12-23 |
2023-06-29 |
Biontech Delivery Technologies Gmbh |
Modular drug production system
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
AU2022422983A1
(en)
*
|
2021-12-23 |
2024-05-16 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
|
CN114249662B
(zh)
*
|
2021-12-27 |
2024-06-21 |
硅羿科技（上海）有限公司 |
一种药用脂质体辅料alc-0315的制备方法
|
|
WO2023126053A1
(en)
|
2021-12-28 |
2023-07-06 |
BioNTech SE |
Lipid-based formulations for administration of rna
|
|
TW202330458A
(zh)
*
|
2021-12-29 |
2023-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
用於遞送的脂質和組成物
|
|
CN114957027B
(zh)
|
2022-01-13 |
2023-05-19 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023141586A1
(en)
|
2022-01-21 |
2023-07-27 |
Orna Therapeutics, Inc. |
Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
CN114409554A
(zh)
*
|
2022-01-27 |
2022-04-29 |
英维沃生物科技(苏州)有限公司 |
一种新型阳离子脂质化合物及其组合物和用途
|
|
CA3242744A1
(en)
|
2022-01-27 |
2023-08-03 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
CN116514671A
(zh)
*
|
2022-01-30 |
2023-08-01 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
CN116554042A
(zh)
*
|
2022-01-30 |
2023-08-08 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
CN120420422A
(zh)
*
|
2022-01-30 |
2025-08-05 |
康希诺生物股份公司 |
一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
|
|
AU2023216437A1
(en)
|
2022-02-02 |
2024-08-15 |
BioNTech SE |
Agents and methods for targeted delivery of nucleic acids to cells
|
|
IL314516A
(en)
|
2022-02-02 |
2024-09-01 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
TW202345863A
(zh)
|
2022-02-09 |
2023-12-01 |
美商現代公司 |
黏膜投與方法及調配物
|
|
EP4479085A1
(en)
|
2022-02-18 |
2024-12-25 |
ModernaTX, Inc. |
Mrnas encoding checkpoint cancer vaccines and uses thereof
|
|
EP4482819A2
(en)
*
|
2022-02-24 |
2025-01-01 |
Vivasor, Inc. |
Novel ionizable cationic lipids
|
|
CN118804743A
(zh)
*
|
2022-03-04 |
2024-10-18 |
益杰立科(上海)生物科技有限公司 |
靶向递送系统和方法
|
|
JP2025509607A
(ja)
|
2022-03-14 |
2025-04-11 |
ジェネレーション バイオ カンパニー |
異種プライムブーストワクチン組成物及び使用の方法
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
CN116813493A
(zh)
*
|
2022-03-21 |
2023-09-29 |
苏州科锐迈德生物医药科技有限公司 |
一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
|
|
CN114380724B
(zh)
*
|
2022-03-23 |
2022-05-24 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
CN119072464A
(zh)
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
CN114890907B
(zh)
*
|
2022-03-31 |
2023-10-31 |
荣灿生物医药技术(上海)有限公司 |
一种阳离子脂质化合物及其制备方法和应用
|
|
WO2023193892A1
(en)
*
|
2022-04-05 |
2023-10-12 |
BioNTech SE |
Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same
|
|
CA3255619A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
WO2023201204A1
(en)
|
2022-04-11 |
2023-10-19 |
Modernatx, Inc. |
Detection of mrna purity in a mixture
|
|
KR20250007577A
(ko)
|
2022-04-27 |
2025-01-14 |
상하이 레제네리드 테라피즈 컴퍼니 리미티드 |
핵산 작제물 및 이의 응용
|
|
EP4522743A1
(en)
|
2022-05-09 |
2025-03-19 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods of use for treating proliferative disorders
|
|
JP2025516674A
(ja)
|
2022-05-13 |
2025-05-30 |
ビオンテック エスエー |
Ｈｉｖを標的とするｒｎａ組成物
|
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
|
CA3253047A1
(en)
|
2022-05-13 |
2025-07-04 |
Shanghai Regenelead Therapies Co., Ltd |
CONSTRUCTION OF NUCLEIC ACIDS INCLUDING A UTR AND ITS USE
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023225524A1
(en)
|
2022-05-17 |
2023-11-23 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
IL316504A
(en)
|
2022-05-25 |
2024-12-01 |
BioNTech SE |
RNA compositions for the delivery of monkeypox antigens and related methods
|
|
CN119212720A
(zh)
|
2022-05-25 |
2024-12-27 |
库瑞瓦格欧洲股份公司 |
编码大肠杆菌FimH抗原性多肽的基于核酸的疫苗
|
|
WO2023230601A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
Identification of nanoparticles for preferential tissue or cell targeting
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
CN119998446A
(zh)
|
2022-06-07 |
2025-05-13 |
斯克里贝治疗公司 |
用于靶向pcsk9的组合物和方法
|
|
CN119604304A
(zh)
|
2022-06-18 |
2025-03-11 |
葛兰素史克生物有限公司 |
包含非翻译区或编码来自严重急性呼吸道冠状病毒2奥密克戎毒株刺突蛋白的区段的重组rna分子
|
|
CN114773217B
(zh)
|
2022-06-20 |
2022-10-18 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
CN119998259A
(zh)
|
2022-06-23 |
2025-05-13 |
特恩生物技术公司 |
脂质结构及包含其的组合物
|
|
CN114989182B
(zh)
*
|
2022-06-23 |
2023-06-23 |
尧唐(上海)生物科技有限公司 |
脂质化合物、包含其的组合物及应用
|
|
WO2023248128A1
(en)
|
2022-06-23 |
2023-12-28 |
Pfizer Inc. |
Use of a spray freeze-drying process for the lyophilization of a mrna-encapsulating lipid nanoparticles formulation
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
EP4544074A1
(en)
|
2022-06-24 |
2025-04-30 |
ModernaTX, Inc. |
Methods of producing rna
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
KR20250040656A
(ko)
|
2022-07-06 |
2025-03-24 |
몰레큘라 악시옴, 엘엘씨 |
췌장암을 치료하기 위한 조성물 및 방법
|
|
EP4551247A1
(en)
|
2022-07-07 |
2025-05-14 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Immunogens and methods for inducing an immune response
|
|
CN119384273A
(zh)
|
2022-07-11 |
2025-01-28 |
传信生物医药(苏州)有限公司 |
用于核酸的器官特异性递送组合物
|
|
CN119731150A
(zh)
*
|
2022-07-15 |
2025-03-28 |
深圳深信生物科技有限公司 |
一种氨基脂质化合物、其制备方法、组合物和应用
|
|
AU2023311964A1
(en)
|
2022-07-18 |
2025-01-30 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
WO2024019936A1
(en)
|
2022-07-20 |
2024-01-25 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
KR20250044720A
(ko)
|
2022-08-01 |
2025-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
면역조절 단백질 및 관련 방법
|
|
JP2025527245A
(ja)
|
2022-08-01 |
2025-08-20 |
ビオンテック・ソシエタス・エウロパエア |
両親媒性オリゴエチレングリコール（ｏｅｇ）コンジュゲート化合物を含む核酸組成物およびそのような化合物および組成物を使用する方法
|
|
CN114989027B
(zh)
*
|
2022-08-03 |
2023-01-31 |
深圳市瑞吉生物科技有限公司 |
用于递送核酸的阳离子脂质化合物和组合物及用途
|
|
IL318534A
(en)
|
2022-08-03 |
2025-03-01 |
BioNTech SE |
RNA for preventing or treating tuberculosis
|
|
WO2024027910A1
(en)
|
2022-08-03 |
2024-02-08 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024032753A1
(zh)
*
|
2022-08-12 |
2024-02-15 |
上海蓝鹊生物医药有限公司 |
含氮链状化合物、其制备方法、包含其的组合物和应用
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
AU2023325407A1
(en)
|
2022-08-19 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
CN115557875B
(zh)
*
|
2022-08-19 |
2025-01-03 |
上海耐澄生物科技有限公司 |
一种脂质化合物及脂质纳米颗粒
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
AU2023334610A1
(en)
|
2022-08-31 |
2025-03-13 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
EP4585586A4
(en)
|
2022-09-09 |
2025-12-03 |
Xiamen Sinopeg Biotech Co Ltd |
CARBON CORE CATIONIC LIPID
|
|
WO2024057209A1
(en)
|
2022-09-15 |
2024-03-21 |
Pfizer Inc. |
Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
|
|
WO2024057237A1
(en)
|
2022-09-16 |
2024-03-21 |
Pfizer Inc. |
Lipid nanoparticles
|
|
TW202412741A
(zh)
*
|
2022-09-19 |
2024-04-01 |
大陸商蘇州盛迪亞生物醫藥有限公司 |
一種製備２－羥乙基胺基己酸酯類化合物方法及其應用
|
|
JP2025533527A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
JP2025533541A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
肝病期抗原の送達のための組成物及び関連方法
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
IL319682A
(en)
|
2022-10-06 |
2025-05-01 |
BioNTech SE |
RNA complexes targeting claudin-18.2
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4608441A1
(en)
|
2022-10-27 |
2025-09-03 |
Pfizer Inc. |
Immunogenic compositions against influenza and rsv
|
|
TWI888970B
(zh)
|
2022-10-27 |
2025-07-01 |
美商輝瑞大藥廠 |
Rna分子
|
|
WO2024089229A1
(en)
|
2022-10-28 |
2024-05-02 |
CureVac SE |
Improved formulations comprising lipid-based carriers encapsulating rna
|
|
WO2024089638A1
(en)
|
2022-10-28 |
2024-05-02 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
CN115417778B
(zh)
*
|
2022-11-01 |
2023-06-20 |
北京华芢生物技术有限公司 |
可离子化的阳离子脂c5及由其组成的纳米脂质体颗粒
|
|
CN115433099B
(zh)
*
|
2022-11-03 |
2023-06-16 |
北京华芢生物技术有限公司 |
可离子化的阳离子脂c6及由其组成的纳米脂质体颗粒
|
|
JP2025538939A
(ja)
|
2022-11-04 |
2025-12-03 |
ファイザー・インク |
脂質化合物およびその使用
|
|
CN120076798A
(zh)
*
|
2022-11-06 |
2025-05-30 |
斯微(上海)生物科技股份有限公司 |
一种脂质组合物
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
CN120435298A
(zh)
|
2022-11-08 |
2025-08-05 |
旗舰创业创新第六有限责任公司 |
用于产生环状多核糖核苷酸的组合物和方法
|
|
AU2023375897A1
(en)
|
2022-11-08 |
2025-06-12 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202425959A
(zh)
|
2022-11-08 |
2024-07-01 |
美商歐納醫療公司 |
遞送多核苷酸的脂質及奈米顆粒組合物
|
|
CN120359023A
(zh)
|
2022-11-10 |
2025-07-22 |
赛欧生物医药股份有限公司 |
包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物
|
|
CN120265279A
(zh)
|
2022-11-21 |
2025-07-04 |
翻译生物公司 |
信使rna的干粉配制品的组合物及其使用方法
|
|
KR20250096760A
(ko)
|
2022-11-24 |
2025-06-27 |
더미디엄 테라퓨틱스 컴퍼니 리미티드 |
핵산 전달을 위한 신규 지질 및 지질 나노입자 조성물
|
|
KR20250131271A
(ko)
|
2022-12-01 |
2025-09-02 |
제너레이션 바이오 컴퍼니 |
신규한 폴리글리세롤-접합된 지질 및 이를 포함하는 지질 나노입자 조성물
|
|
KR20250114116A
(ko)
|
2022-12-01 |
2025-07-28 |
제너레이션 바이오 컴퍼니 |
세포 표적화를 위한 스텔스 지질 나노입자 조성물
|
|
KR20250129819A
(ko)
|
2022-12-01 |
2025-08-29 |
제너레이션 바이오 컴퍼니 |
핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
KR20250115452A
(ko)
|
2022-12-08 |
2025-07-30 |
리코드 테라퓨틱스, 인크. |
지질 나노입자 조성물 및 이의 용도
|
|
WO2024121814A1
(en)
|
2022-12-09 |
2024-06-13 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
WO2024127181A1
(en)
|
2022-12-11 |
2024-06-20 |
Pfizer Inc. |
Immunogenic compositions against influenza and rsv
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2023394992A1
(en)
|
2022-12-15 |
2025-07-31 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
EP4637812A1
(en)
|
2022-12-19 |
2025-10-29 |
GlaxoSmithKline Biologicals S.A. |
Hepatitis b compositions
|
|
KR20240096964A
(ko)
|
2022-12-19 |
2024-06-27 |
주식회사 녹십자 |
핵산 전달용 사이클로알칸계 지질 화합물 및 이를 포함하는 지질 나노입자
|
|
CN120475991A
(zh)
|
2022-12-20 |
2025-08-12 |
赛诺菲巴斯德有限公司 |
鼻病毒mRNA疫苗
|
|
CN119095585A
(zh)
*
|
2022-12-21 |
2024-12-06 |
苏州艾博生物科技有限公司 |
包含固醇修饰的磷脂的脂质纳米颗粒
|
|
EP4637717A1
(en)
|
2022-12-23 |
2025-10-29 |
Pfizer Inc. |
Lipid particle compositions and methods of use thereof
|
|
KR20250121437A
(ko)
*
|
2022-12-28 |
2025-08-12 |
아스텔라스세이야쿠 가부시키가이샤 |
4-아미노피페리딘 화합물, 그의 지질 나노입자, 및 그것을 포함하는 의약 조성물
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
WO2024141786A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
|
TW202432572A
(zh)
|
2022-12-29 |
2024-08-16 |
大陸商仁景（蘇州）生物科技有限公司 |
用於預防或治療ｈｐｖ感染相關疾病的多核苷酸分子
|
|
CN116375592B
(zh)
*
|
2023-01-05 |
2025-05-16 |
北京悦康科创医药科技股份有限公司 |
长效低毒的新型阳离子脂质化合物及其组合物
|
|
CN116178193B
(zh)
*
|
2023-01-05 |
2023-07-28 |
北京悦康科创医药科技股份有限公司 |
高效低毒且稳定性表达的阳离子脂质化合物及其组合物
|
|
CN115677518B
(zh)
*
|
2023-01-05 |
2023-04-14 |
北京悦康科创医药科技股份有限公司 |
用于递送核酸的可电离阳离子脂质化合物和组合物及用途
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
US20240238473A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
CN120813373A
(zh)
|
2023-01-16 |
2025-10-17 |
辉瑞大药厂 |
诱导针对水痘带状疱疹病毒的免疫反应的免疫原性组合物和方法
|
|
WO2024153324A1
(en)
|
2023-01-18 |
2024-07-25 |
BioNTech SE |
Rna formulations for pharmaceutical use
|
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
|
WO2024161249A1
(en)
|
2023-01-31 |
2024-08-08 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
TW202438515A
(zh)
|
2023-02-06 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫調節組合物及相關方法
|
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
|
CN115784921B
(zh)
|
2023-02-08 |
2023-05-05 |
北京悦康科创医药科技股份有限公司 |
肝外靶向高效低毒的阳离子脂质化合物及其组合物
|
|
KR20250151427A
(ko)
|
2023-02-13 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
치료적 조성물을 위한 절단성 링커 함유 이온화 가능한 지질 및 지질 담체
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
EP4665856A2
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified cytosine
|
|
WO2024178305A1
(en)
|
2023-02-24 |
2024-08-29 |
Modernatx, Inc. |
Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
|
|
CN121002196A
(zh)
|
2023-02-28 |
2025-11-21 |
百欧恩泰欧洲股份公司 |
用于多种编码核酸的接头序列效力测定
|
|
WO2024180363A1
(en)
|
2023-02-28 |
2024-09-06 |
BioNTech SE |
Linker sequence potency assays for multiple coding nucleic acids
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
AU2024234022A1
(en)
|
2023-03-09 |
2025-08-28 |
BioNTech SE |
Peptidoglycan hydrolases with bactericidal activity
|
|
AU2024235803A1
(en)
|
2023-03-15 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024192277A2
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
WO2024194767A1
(en)
|
2023-03-17 |
2024-09-26 |
BioNTech SE |
Automated drug production system
|
|
CN118666726A
(zh)
*
|
2023-03-17 |
2024-09-20 |
尧唐(上海)生物科技有限公司 |
递送治疗剂的脂质化合物及其制备方法与应用
|
|
WO2024193827A1
(en)
|
2023-03-23 |
2024-09-26 |
BioNTech SE |
Stabilized nucleic acid compositions and methods for preparing, storing and using the same
|
|
AU2024246046A1
(en)
|
2023-03-29 |
2025-10-02 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
TW202444921A
(zh)
|
2023-03-29 |
2024-11-16 |
美商斯奎柏治療公司 |
用於靶向lpa之組合物及方法
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AU2024248139A1
(en)
|
2023-03-29 |
2025-09-25 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2024206835A1
(en)
|
2023-03-30 |
2024-10-03 |
Modernatx, Inc. |
Circular mrna and production thereof
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
AR132276A1
(es)
|
2023-04-07 |
2025-06-11 |
Takeda Pharmaceuticals Co |
Complejo de conjugación
|
|
WO2024209418A1
(en)
|
2023-04-07 |
2024-10-10 |
BioNTech SE |
Heating and cooling jacket for fluid vessels
|
|
KR20250171373A
(ko)
|
2023-04-12 |
2025-12-08 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
미스센스 돌연변이 교정용 trem
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
WO2024216214A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024216212A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
WO2024213776A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Rna for preventing or treating tuberculosis
|
|
CN120936375A
(zh)
|
2023-04-14 |
2025-11-11 |
生物技术欧洲股份公司 |
Hiv疫苗
|
|
WO2024218166A1
(en)
|
2023-04-17 |
2024-10-24 |
Sanofi |
Reconstitutable dry powder formulations and methods of use thereof
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
CN117384055B
(zh)
*
|
2023-04-27 |
2024-11-19 |
仁景(苏州)生物科技有限公司 |
用于递送治疗剂的可电离脂质及其用途
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
AU2024265158A1
(en)
|
2023-05-03 |
2025-11-06 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
AU2024269222A1
(en)
|
2023-05-05 |
2025-10-09 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024249954A1
(en)
|
2023-05-31 |
2024-12-05 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2024256962A1
(en)
|
2023-06-14 |
2024-12-19 |
Pfizer Inc. |
Method for stabilizing rna
|
|
WO2024255415A1
(zh)
*
|
2023-06-16 |
2024-12-19 |
北京剂泰医药科技有限公司 |
一种快速代谢的脂质化合物
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025003760A1
(en)
|
2023-06-28 |
2025-01-02 |
Sanofi |
Sterol analogs in lipid nanoparticle formulations
|
|
AU2024310564A1
(en)
|
2023-06-29 |
2025-11-27 |
BioNTech SE |
Modular multiplatform system for mrna drug production
|
|
WO2025006385A1
(en)
|
2023-06-30 |
2025-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel malaria vaccine comprising ama1 and ron2 antigens
|
|
WO2025002359A1
(zh)
*
|
2023-06-30 |
2025-01-02 |
深圳深信生物科技有限公司 |
水痘带状疱疹病毒(vzv)疫苗
|
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性ｔｌｒ７／８佐劑及其用途
|
|
WO2025017476A1
(en)
|
2023-07-19 |
2025-01-23 |
Pfizer Inc. |
Lipid nanoparticles comprising polymer-conjugated lipids and uses thereof
|
|
WO2025021277A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Agents and methods for targeted delivery of cytokines to immune cells
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
US20250092426A1
(en)
|
2023-07-25 |
2025-03-20 |
Flagship Pioneering Innovations Vii, Llc |
Cas endonucleases and related methods
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026553A1
(en)
|
2023-08-02 |
2025-02-06 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025027576A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2025036992A1
(en)
|
2023-08-16 |
2025-02-20 |
CureVac SE |
Rna conjugates
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025054236A2
(en)
*
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025051994A1
(en)
|
2023-09-07 |
2025-03-13 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
CN119591513A
(zh)
*
|
2023-09-11 |
2025-03-11 |
苏州星核迪赛生物技术有限公司 |
局部递送药物的材料及其应用
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025057115A2
(en)
|
2023-09-15 |
2025-03-20 |
Pfizer Inc. |
Methods and compositions for continuous production of nucleic acids
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025061863A1
(en)
|
2023-09-20 |
2025-03-27 |
BioNTech SE |
Method
|
|
WO2025064850A1
(en)
|
2023-09-22 |
2025-03-27 |
BioNTech SE |
Rna constructs with n-terminal degrons to enhance an immune response
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025082397A1
(zh)
*
|
2023-10-19 |
2025-04-24 |
仁景(苏州)生物科技有限公司 |
用于递送的脂质化合物及脂质纳米颗粒
|
|
WO2025088088A1
(en)
|
2023-10-27 |
2025-05-01 |
CureVac SE |
Rna composition for improving cell therapy
|
|
TW202527962A
(zh)
|
2023-10-31 |
2025-07-16 |
德商拜恩技術股份公司 |
粒子、組合物及方法
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
CN118147134B
(zh)
|
2023-11-06 |
2025-02-25 |
北京悦康科创医药科技股份有限公司 |
靶向调控PCSK9基因表达的siRNA及其应用
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
CN117550985B
(zh)
*
|
2023-11-08 |
2025-02-18 |
深圳厚存纳米药业有限公司 |
一种脂质化合物及其用途
|
|
WO2025103803A1
(en)
|
2023-11-13 |
2025-05-22 |
CureVac SE |
Immunotherapy against neuronal and brain tumors
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
CA3254064A1
(en)
|
2023-11-15 |
2025-05-21 |
BioNTech SE |
Immunogenic compositions against SARS-CoV-2
|
|
WO2025106754A1
(en)
|
2023-11-15 |
2025-05-22 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2025106915A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
|
|
WO2025106806A1
(en)
|
2023-11-17 |
2025-05-22 |
Acuitas Therapeutics, Inc. |
Pegylated lipids
|
|
WO2025106930A1
(en)
|
2023-11-17 |
2025-05-22 |
Sail Biomedicines, Inc. |
Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
EP4559898A1
(en)
|
2023-11-24 |
2025-05-28 |
AldexChem Kft. |
Novel ionizable cationic lipids containing thioether linkage
|
|
WO2025114520A1
(en)
|
2023-12-01 |
2025-06-05 |
Coave Therapeutics |
Ionizable lipid nanoparticles
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025128696A1
(en)
|
2023-12-12 |
2025-06-19 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025126019A1
(en)
|
2023-12-13 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025132122A1
(en)
|
2023-12-13 |
2025-06-26 |
Berlin Institute Of Health |
Methods of delivering therapeutics using lipid nanoparticles
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025126071A1
(en)
|
2023-12-14 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025126118A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2025126113A1
(en)
|
2023-12-15 |
2025-06-19 |
Pfizer Inc. |
Lipid compounds and uses thereof
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025134046A1
(en)
|
2023-12-22 |
2025-06-26 |
Pfizer Inc. |
Methods and vaccine compositions for lyme disease
|
|
WO2025144938A1
(en)
|
2023-12-26 |
2025-07-03 |
Emmune, Inc. |
Systems for nucleic acid transfer
|
|
CN117820149B
(zh)
*
|
2023-12-29 |
2025-01-07 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025149492A1
(en)
|
2024-01-08 |
2025-07-17 |
BioNTech SE |
Rna encoding an immune inhibitory il-1 family member
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025166238A1
(en)
|
2024-01-31 |
2025-08-07 |
Orna Therapeutics, Inc. |
Fast-shedding polyethylene glycol lipids
|
|
WO2025166323A2
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting lipoprotein (a) expression
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025174858A1
(en)
|
2024-02-15 |
2025-08-21 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025186719A1
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
WO2025191415A1
(en)
|
2024-03-11 |
2025-09-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
WO2025202834A1
(en)
|
2024-03-26 |
2025-10-02 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
CN118255678B
(zh)
*
|
2024-03-28 |
2024-12-24 |
荣灿生物医药技术(上海)有限公司 |
一种可电离脂质化合物及其应用
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025210520A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for inducing an immunological response
|
|
WO2025210521A1
(en)
|
2024-04-04 |
2025-10-09 |
Genevant Sciences Gmbh |
Lipid nanoparticles for stimulating t cells
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217131A1
(en)
*
|
2024-04-08 |
2025-10-16 |
Popvax Private Limited |
Novel lipids for delivery of nucleic acid therapeutics
|
|
WO2025217264A1
(en)
|
2024-04-10 |
2025-10-16 |
Acuitas Therapeutics, Inc. |
Cationic lipid compounds for use in lipid nanoparticles
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118319880B
(zh)
*
|
2024-04-15 |
2025-02-07 |
荣灿生物医药技术(上海)有限公司 |
靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用
|
|
WO2025224684A1
(en)
|
2024-04-24 |
2025-10-30 |
BioNTech SE |
Compositions and methods for producing engineered immune cells
|
|
WO2025228975A1
(en)
|
2024-04-29 |
2025-11-06 |
BioNTech SE |
Particles, compositions and methods
|
|
WO2025231114A1
(en)
|
2024-05-01 |
2025-11-06 |
Acuitas Therapeutics, Inc. |
Method of using lipid nanoparticles for intramuscular delivery
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025238563A1
(en)
|
2024-05-17 |
2025-11-20 |
Pfizer Inc. |
Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
|
|
WO2025240833A1
(en)
|
2024-05-17 |
2025-11-20 |
Acuitas Therapeutics, Inc. |
Galnac lipid compounds for use in lipid nanoparticles
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025242815A1
(en)
|
2024-05-23 |
2025-11-27 |
CureVac SE |
Immunotherapy of squamous cell carcinoma
|
|
CN118240844B
(zh)
|
2024-05-27 |
2024-12-13 |
北京悦康科创医药科技股份有限公司 |
带状疱疹mRNA疫苗及其制备方法和应用
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
CN119930462B
(zh)
*
|
2025-04-08 |
2025-06-27 |
北京悦康科创医药科技股份有限公司 |
基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途
|